These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 7963811

  • 1. Effect of hyperthermia on cisplatin and carboplatin disposition in the isolated, perfused tumour and skin flap.
    Vaden SL, Page RL, Williams PL, Riviere JE.
    Int J Hyperthermia; 1994; 10(4):563-72. PubMed ID: 7963811
    [Abstract] [Full Text] [Related]

  • 2. Effect of tumor presence on cisplatin and carboplatin: disposition in the isolated, perfused tumor and skin flap.
    Vaden SL, Williams PL, Page RL, Riviere JE.
    Cancer Chemother Pharmacol; 1993; 32(1):31-8. PubMed ID: 8462121
    [Abstract] [Full Text] [Related]

  • 3. Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin.
    Los G, van Vugt MJ, Pinedo HM.
    Br J Cancer; 1994 Feb; 69(2):235-41. PubMed ID: 8297720
    [Abstract] [Full Text] [Related]

  • 4. An in vitro-in vivo validation of the isolated perfused tumor and skin flap preparation as a model of cisplatin delivery to tumors.
    Vaden SL, Page RL, Riviere JE.
    J Pharmacol Toxicol Methods; 1996 Jun; 35(3):173-7. PubMed ID: 8782096
    [Abstract] [Full Text] [Related]

  • 5. Combination treatment of cis- and carboplatin in cancers restricted to the peritoneal cavity in the rat.
    Los G, Tuyt L, van Vugt M, Schornagel J, Pinedo HM.
    Cancer Chemother Pharmacol; 1993 Jun; 32(6):425-33. PubMed ID: 8258189
    [Abstract] [Full Text] [Related]

  • 6. Schedule dependent tumour growth delay, DNA cross-linking and pharmacokinetic parameters in target tissues with cis-diamminedichloroplatinum(II) and etanidazole with or without hyperthermia or radiation.
    Teicher BA, Pfeffer MR, Alvarez Sotomayor E, Herman TS.
    Int J Hyperthermia; 1991 Jun; 7(5):773-84. PubMed ID: 1834752
    [Abstract] [Full Text] [Related]

  • 7. Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model.
    Chang MJ, Yu WD, Reyno LM, Modzelewski RA, Egorin MJ, Erkmen K, Vlock DR, Furmanski P, Johnson CS.
    Cancer Res; 1994 Oct 15; 54(20):5380-6. PubMed ID: 7923169
    [Abstract] [Full Text] [Related]

  • 8. Stable circadian mechanisms of toxicity of two platinum analogs (cisplatin and carboplatin) despite repeated dosages in mice.
    Boughattas NA, Lévi F, Fournier C, Hecquet B, Lemaigre G, Roulon A, Mathé G, Reinberg A.
    J Pharmacol Exp Ther; 1990 Nov 15; 255(2):672-9. PubMed ID: 2243347
    [Abstract] [Full Text] [Related]

  • 9. [Probability of the combination use of cisplatin and carboplatin].
    Kobayashi K, Hino M, Hayashihara K, Niitani H.
    Nihon Gan Chiryo Gakkai Shi; 1990 Nov 20; 25(11):2684-92. PubMed ID: 2277219
    [Abstract] [Full Text] [Related]

  • 10. Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer model.
    Jandial DD, Messer K, Farshchi-Heydari S, Pu M, Howell SB.
    Gynecol Oncol; 2009 Dec 20; 115(3):362-6. PubMed ID: 19775736
    [Abstract] [Full Text] [Related]

  • 11. Effects of temperature on the interaction of cisplatin and carboplatin with cellular DNA.
    Los G, van Vugt MJ, den Engelse L, Pinedo HM.
    Biochem Pharmacol; 1993 Oct 05; 46(7):1229-37. PubMed ID: 8216374
    [Abstract] [Full Text] [Related]

  • 12. [Pharmacokinetic analysis of platinum in the continuous CDDP-CBDCA treatment; its relation to the changes of blood biochemistry].
    Chen JT, Hasumi K.
    Gan To Kagaku Ryoho; 1995 Apr 05; 22(5):653-7. PubMed ID: 7717717
    [Abstract] [Full Text] [Related]

  • 13. Effect of hyperthermia on cisplatin (CDDP) disposition to isolated perfused skin.
    Williams PL, Riviere JE.
    Int J Hyperthermia; 1990 Apr 05; 6(5):923-32. PubMed ID: 2250117
    [Abstract] [Full Text] [Related]

  • 14. Experimental studies of cis-diamminedichloroplatinum (II) and cis-diammine-1, 1-cyclobutandicarboxylate platinum (II) combination therapy for malignant gynecologic tumors.
    Kato N.
    Asia Oceania J Obstet Gynaecol; 1993 Dec 05; 19(4):467-76. PubMed ID: 8135680
    [Abstract] [Full Text] [Related]

  • 15. Effect of whole body hyperthermia on carboplatin disposition and toxicity in dogs.
    Page RL, McEntee MC, Williams PL, George SL, Price GS, Novotney CA, Hauck ML, Riviere JE, Dewhirst MW, Thrall DE.
    Int J Hyperthermia; 1994 Dec 05; 10(6):807-16. PubMed ID: 7884240
    [Abstract] [Full Text] [Related]

  • 16. Cellular pharmacokinetics of carboplatin and cisplatin in relation to their cytotoxic action.
    Los G, Verdegaal E, Noteborn HP, Ruevekamp M, de Graeff A, Meesters EW, ten Bokkel Huinink D, McVie JG.
    Biochem Pharmacol; 1991 Jul 05; 42(2):357-63. PubMed ID: 1859450
    [Abstract] [Full Text] [Related]

  • 17. Absence of whole body hyperthermia effect on cisplatin distribution in spontaneous canine tumors.
    Page RL, Lee J, Riviere JE, Dodge RK, Thrall DE, Dewhirst MW.
    Int J Radiat Oncol Biol Phys; 1995 Jul 15; 32(4):1097-102. PubMed ID: 7607930
    [Abstract] [Full Text] [Related]

  • 18. The chemical reactivity of the modulating agent WR2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin.
    Treskes M, Holwerda U, Klein I, Pinedo HM, van der Vijgh WJ.
    Biochem Pharmacol; 1991 Nov 06; 42(11):2125-30. PubMed ID: 1659819
    [Abstract] [Full Text] [Related]

  • 19. Increased therapeutic efficacy induced by tumor necrosis factor alpha combined with platinum complexes and whole-body hyperthermia in rats.
    Ohno S, Strebel FR, Stephens LC, Siddik ZH, Makino M, Klostergaard J, Tomasovic SP, Khokhar AR, Bull JM.
    Cancer Res; 1992 Aug 01; 52(15):4096-101. PubMed ID: 1638521
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics and antitumor activity of a new platinum compound, cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1, 3- dioxolane]platinum(II), as determined by ex vivo pharmacodynamics.
    Kim DK, Kim HT, Tai JH, Cho YB, Kim TS, Kim KH, Park JG, Hong WS.
    Cancer Chemother Pharmacol; 1995 Aug 01; 37(1-2):1-6. PubMed ID: 7497577
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.